Design, Synthesis, and Biological Activity Study of Antitumor Drugs Containing Aryl Hydrazone Quinazoline

A series of novel quinazoline derivatives containing aromatic hydrazones were synthesized and characterized by ¹H NMR, ¹³C NMR, MS, and IR. The antitumor activity of the compounds was tested using A549 and MKN45 cell lines with gefitinib and foretinib as positive control drugs. By combining its unique molecular docking model, the target derivatives were docked with proteins to explore the binding mode and biological activity of the target derivatives on the EGFR/c-Met dual target, and the ADME data of the compounds were ultimately predicted. The final proof shown that (E)-4-[3-({4-[2-(3-chlorobenzylidene)hydrazineyl]-7-methoxyquinazolin-6-yl}oxy)propyl]morpholine and (E)-4-[3-({4-[2-(2,4-dichlorobenzylidene)hydrazineyl]-7-methoxyquinazolin-6-yl}oxy)propyl]morpholine have high drug-like properties and further research value.